Meta-analysis of 6 studies (39,991 people with PAD; RCTs and non-randomised): rivaroxaban vs control was linked to fewer composite efficacy events (RR 0.84) and acute limb ischaemia (RR 0.65), but more major bleeding (HR 1.54); no clear difference in mortality.
Meta-analysisn = 39,991
Shahzaib et al. Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis